HODO-2224 is under clinical development by Hyundai Pharma and currently in Phase I for Cardiovascular Disease. According to GlobalData, Phase I drugs for Cardiovascular Disease have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HODO-2224’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HODO-2224 overview
HODO-2224 is under development for the treatment of unspecified cardiovascular disease, essential hypertension and primary hypercholesterolemia. It is an incrementally modified fixed-dose drug combination. It is administered through oral route as a tablet .
Hyundai Pharma overview
Hyundai Pharma develops, manufactures and distributes pharmaceutical products, health drinks and medical equipment. The company provides over the counter and prescription drugs in the forms of tablets, capsules, solutions for injections and infusions, suspensions, ointments, creams, gels, and others. It is investigating HDNO-1605, an antidiabetic drug for type 2 diabetes; BPDO-1603 and HDDO-1728 for the treatment of senile dementia. Hyundai Pharma offers products in the therapeutic areas of cardio-vascular, respiratory, endocrinology, central nervous system (CNS), obstetrics or gynecology, gastro-intestinal, dermatology and cancer. The company markets its products through partners and distributors worldwide. Hyundai Pharma is headquartered in Seoul, South Korea.
For a complete picture of HODO-2224’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
